Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) shares hit a new 52-week low during trading on Thursday. The company traded as low as $8.78 and last traded at $8.85, with a volume of 307,526 shares traded. The stock had previously closed at $9.07.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on the company. Wedbush reaffirmed an “outperform” rating and set a $27.00 price objective on shares of Monte Rosa Therapeutics in a research report on Wednesday, September 9th. Benchmark reissued a “buy” rating on shares of Monte Rosa Therapeutics in a report on Monday, October 5th. Guggenheim reissued a “buy” rating and issued a $28.00 target price on shares of Monte Rosa Therapeutics in a research note on Tuesday, August 25th. HC Wainwright started coverage on Monte Rosa Therapeutics in a research note on Thursday, October 1st. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Jefferies Financial Group restated a “buy” rating on shares of Monte Rosa Therapeutics in a report on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Monte Rosa Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.44.
View Our Latest Stock Analysis on Monte Rosa Therapeutics
Monte Rosa Therapeutics Trading Down 3.0%
The business’s 50 day simple moving average is $10.78 and its two-hundred day simple moving average is $16.46. The firm has a market capitalization of $738.29 million, a PE ratio of -6.17 and a beta of 1.40.
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.24. Monte Rosa Therapeutics had a negative return on equity of 30.14% and a negative net margin of 186.24%. The firm had revenue of $54.37 million for the quarter, compared to the consensus estimate of $33.87 million. As a group, equities research analysts anticipate that Monte Rosa Therapeutics, Inc. will post -0.94 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Allworth Financial LP purchased a new stake in shares of Monte Rosa Therapeutics during the 2nd quarter valued at about $30,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Monte Rosa Therapeutics by 14.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 17,166 shares of the company’s stock worth $202,000 after buying an additional 2,121 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in shares of Monte Rosa Therapeutics by 842.3% in the third quarter. Sterling Capital Management LLC now owns 2,450 shares of the company’s stock worth $29,000 after buying an additional 2,190 shares during the last quarter. Profund Advisors LLC grew its position in Monte Rosa Therapeutics by 7.6% during the third quarter. Profund Advisors LLC now owns 32,406 shares of the company’s stock valued at $387,000 after buying an additional 2,295 shares during the period. Finally, Blue Owl Capital Holdings LP bought a new stake in Monte Rosa Therapeutics during the third quarter valued at approximately $29,000. 79.96% of the stock is owned by hedge funds and other institutional investors.
Monte Rosa Therapeutics Company Profile
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments. The company’s research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway.
Further Reading
- Five stocks we like better than Monte Rosa Therapeutics
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
